Deutsche Bank AG Makes New Investment in Lantheus Holdings, Inc. $LNTH

Deutsche Bank AG bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 248,743 shares of the medical equipment provider’s stock, valued at approximately $27,596,000.

Several other large investors have also recently made changes to their positions in LNTH. Versant Capital Management Inc boosted its position in Lantheus by 33.0% during the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 146 shares in the last quarter. Abel Hall LLC boosted its stake in Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 172 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Lantheus by 6.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after purchasing an additional 202 shares in the last quarter. Finally, Vident Advisory LLC boosted its position in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on LNTH shares. CJS Securities lowered Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Mizuho cut their price target on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Finally, Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $108.11.

Lantheus Trading Down 0.3%

Shares of NASDAQ:LNTH opened at $99.97 on Friday. The business’s 50 day moving average price is $104.08 and its 200-day moving average price is $90.35. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of 24.15 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the business posted $1.57 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.